|
|
|
12 May 2006 |
Threshold Pharmaceuticals Announces Changes to TH-070 Clinical Development Program
|
|
12 May 2006 |
Neoprobe Receives Regulatory Clearance for Lymphoseek Clinical Study; Lymphoseek Trial Removed from FDA Clinical Hold
|
|
11 May 2006 |
PBT2 -Phase IIa Clinical Trial in Alzheimer’s Disease Patients
|
|
11 May 2006 |
Neurogen Announces Positive Phase II Clinical Trial Results for Insomnia Drug
|
|
11 May 2006 |
NeuroMedix announces that Minozac reduces brain inflammation in a mouse model of traumatic brain injury
|
|
11 May 2006 |
Cytochroma announces significant results with CTA002, a vitamin D analog and enzyme inhibitor, in a prostate cancer model
|
|
11 May 2006 |
Ceragenix Pharmaceuticals Enters Into Research Agreement With Johns Hopkins Burn Center to Evaluate Ceragenin Antimicrobial Wound Dressing
|
|
11 May 2006 |
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
|
|
11 May 2006 |
Green light in Europe for Schering’s new low-dose contraceptive, Yasminelle
|
|
11 May 2006 |
NephroGenex licenses Pyridorin™ for diabetic nephropathy and acute renal failure
|
|
11 May 2006 |
NeoRx Initiates Clinical Trial of Picoplatin in Colorectal Cancer and Announces Name Change to Poniard Pharmaceuticals and Relocation of Corporate Headquarters
|
|
10 May 2006 |
Tranzyme Pharma Announces Successful Completion of Phase I Clinical Trial of its Novel Ghrelin Agonist, TZP-101
|
|
10 May 2006 |
Incyte Begins Phase I Study of New HIV Drug in Healthy Volunteers
|
|
10 May 2006 |
Five years after approval, Glivec underscores the promise of targeted therapy to provide sustained disease control
|
|
10 May 2006 |
Eisai and Nitto Denko Sign a Joint Development Agreement on a Transdermal Patch Formulation of Aricept
|
|
10 May 2006 |
Inflazyme Announces Start of Phase IIb Trial with IPL512,602 for Asthma
|
|
10 May 2006 |
Pharmacyclics to Submit New Drug Application for Xcytrin(R) for Treatment of Lung Cancer Patients With Brain Metastases
|
|
09 May 2006 |
Chelsea Therapeutics and Active Biotech to Co-Develop Portfolio of Therapeutics Targeting Autoimmune Disease and Transplant Rejection
|
|
09 May 2006 |
Lilly Submits Cymbalta® Supplemental New Drug Application for Generalized Anxiety Disorder
|
|
09 May 2006 |
Eisai Will Initiate Phase I Study for E2012, a Potential New Treatment for Alzheimer's Disease
|
|
09 May 2006 |
Chelsea Therapeutics to Seek Orphan Drug Status and Begin Development of Droxidopa for Neurogenic Orthostatic Hypotension
|
|
09 May 2006 |
New Findings From Two Studies on Lybrel Presented at ACOG
|
|
09 May 2006 |
Mission Pharmacal Completes Phase III Study of Tindamax(R) for the Treatment of Bacterial Vaginosis
|
|
09 May 2006 |
Imagenetix Announces 1-Tetradecanol Complex Acts to Inhibit Bacteria and Enzymes Associated with Oral Disease, Sepsis and Inflammation
|
|
09 May 2006 |
Chelsea Therapeutics to Seek Orphan Drug Status and Begin Development of Droxidopa for Neurogenic Orthostatic Hypotension
|
|
08 May 2006 |
InterMune Presents Preclinical Data Identifying a Principal Mechanism of Anti-Fibrotic Action for Pirfenidone
|
|
08 May 2006 |
Frova(R) Meets Primary Endpoint in Second Phase III Study for Prevention of Menstrual Migraine
|
|
06 May 2006 |
Cardiome Reports Additional Phase 1 Trial Data for Oral RSD1235
|
|
05 May 2006 |
VIVUS Announces Positive Phase 3 Clinical Trial Results for Evamist(TM) - The First Transdermal Spray for the Treatment of Menopausal Symptoms
|
|
05 May 2006 |
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
|
|
05 May 2006 |
ORADUR™ Technology Milestone: Remoxy™ (ORADUR-based oxycodone) Commences Pivotal Phase III Program
|
|
05 May 2006 |
Anacor Presents Data on Novel Mechanism of Action for Its Topical Antifungal Treatment, AN2690
|
|
05 May 2006 |
Independent Report Received on PBT2 Phase I Clinical Trial
|
|
05 May 2006 |
Adeza Submits New Drug Application For Gestiva to Prevent Preterm Births; NIH Study Finds 34% Reduction in Preterm Births; Therapy Recommended by ACOG
|
|
05 May 2006 |
Combined Use Of Atacand(R) And ACE Inhibitor Improves Heart Failure Outcomes More Than ACE Inhibitor Alone
|
|
05 May 2006 |
Phase III Trial Of Oral Cladribine, A Novel Investigational Therapy For Multiple Sclerosis, Begins In The United States
|
|
05 May 2006 |
Corgentech Presents Additional Phase 2 Data Demonstrating 4975 Provides Early, Sustained Relief of Pain and improved function in Elbow Tendonitis
|
|
05 May 2006 |
Palatin Technologies And King Pharmaceuticals Complete Enrollment In Two Phase IIb Clinical Trials Evaluating Bremelanotide In Patients With Erectile Dysfunction
|
|
05 May 2006 |
GlaxoSmithKline and Adolor Present Positive Results from a Clinical Study of Alvimopan (Entereg(R))
|
|
04 May 2006 |
Cephalon's Fentanyl Effervescent Buccal Tablet Reduces Intensity of Breakthrough Pain in Cancer Patients
|
|
04 May 2006 |
Investigators Present Final Results of Three Groundbreaking Trials of Ligand's AVINZA(R) at the American Pain Society Meeting
|
|
04 May 2006 |
ISTA Pharmaceuticals(R) Announces Study Indicating Twice-Daily Dosing of Xibrom(TM) as Equivalent to Four Times a Day of Other Treatments
|
|
04 May 2006 |
AstraZeneca Discontinues Development of GALIDA TM (tesaglitazar)
|
|
04 May 2006 |
NicOx initiates new trial to establish HCT 3012 as osteoarthritis treatment with beneficial blood pressure profile
|
|
04 May 2006 |
XTL Biopharmaceuticals Ltd. Initiates Patient Dosing in Phase 1 Clinical Trial of XTL-2125, an Oral, Non-Nucleoside Polymerase Inhibitor for the Treatment of Hepatitis C
|
|
04 May 2006 |
deCODE Announces Special Protocol Assessment Agreement with the FDA for Phase III Clinical Trial of DG031
|
|
04 May 2006 |
Myogen Reports Results for the Integrated Analysis of ARIES-1 and ARIES-2 Pivotal Trials of Ambrisentan in Pulmonary Arterial Hypertension; Significant Improvements Observed for All Primary and Secondary Endpoints
|
|
04 May 2006 |
Voyager Pharmaceutical Corporation Completes Second Phase II Clinical Study for Alzheimer's Disease
|
|
03 May 2006 |
Molecular Pharmacology to Acquire Topical Cox-2 Inhibitor Candidate as Part of Australian Transaction
|
|
03 May 2006 |
GTx, Inc. Attains Enrollment Goal for Phase III PIN Clinical Trial
|
| |
|
Results 5101 - 5150 of 5705 |
